Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cortex And Poniard Cut Their Workforces

by Ann M. Thayer
March 30, 2009 | A version of this story appeared in Volume 87, Issue 13

Cortex Pharmaceuticals is restructuring its operations and halving its workforce of about 30. To increase its available cash, the company has also reduced the salaries of its executives and is exploring licensing, partnering, and other business options. It will focus on developing CX717 for opioid-induced respiratory depression and CX1739 for sleep apnea while scaling back its early-stage programs. Meanwhile, Poniard Pharmaceuticals is directing its resources toward its late-stage oncology candidate, picoplatin. It has discontinued preclinical research and trimmed its workforce by about 12%, or eight employees.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.